AVENUE SOLUTIONS

Lobbying for JAZZ PHARMACEUTICALS, INC. · Specialty pharmaceuticals

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · California · House · Senate · $50,000.00 income · posted Apr 20, 2026

Lobbying activity 2

Health Issues

Drug safety, prescription drug abuse, value of prescription drugs; Issues related to drug pricing, including orphan drugs; Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders

Medicare/Medicaid

Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to implementation of the Inflation Reduction Act of 2022

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.